报价延迟最少15分钟:2026/09/05 00:38 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.25/-3.73
|
|
企业价值
2.05B
|
| 资产负债 |
|
每股账面净值
8.63
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape. |
